BARBIERI, Elena
 Distribuzione geografica
Continente #
NA - Nord America 4.933
EU - Europa 2.419
AS - Asia 2.131
SA - Sud America 317
Continente sconosciuto - Info sul continente non disponibili 69
AF - Africa 51
OC - Oceania 10
Totale 9.930
Nazione #
US - Stati Uniti d'America 4.845
SG - Singapore 623
IT - Italia 621
CN - Cina 532
GB - Regno Unito 500
IE - Irlanda 346
HK - Hong Kong 263
BR - Brasile 234
SE - Svezia 217
VN - Vietnam 215
DE - Germania 212
BD - Bangladesh 153
FI - Finlandia 110
UA - Ucraina 105
RU - Federazione Russa 92
FR - Francia 66
IN - India 63
CA - Canada 51
TR - Turchia 51
KR - Corea 45
BG - Bulgaria 37
ID - Indonesia 35
AR - Argentina 24
NL - Olanda 21
IQ - Iraq 20
IR - Iran 18
ZA - Sudafrica 18
ES - Italia 15
MX - Messico 15
PL - Polonia 15
JP - Giappone 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
CL - Cile 11
CO - Colombia 11
EC - Ecuador 11
MY - Malesia 11
PK - Pakistan 10
AZ - Azerbaigian 9
AU - Australia 8
TW - Taiwan 7
UZ - Uzbekistan 7
AT - Austria 6
BE - Belgio 6
EG - Egitto 6
NG - Nigeria 6
PH - Filippine 6
PY - Paraguay 6
CZ - Repubblica Ceca 5
HN - Honduras 5
JM - Giamaica 5
JO - Giordania 5
LT - Lituania 5
MT - Malta 5
TH - Thailandia 5
AL - Albania 4
DO - Repubblica Dominicana 4
KE - Kenya 4
MA - Marocco 4
NP - Nepal 4
PT - Portogallo 4
SA - Arabia Saudita 4
SI - Slovenia 4
UY - Uruguay 4
CH - Svizzera 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
EU - Europa 3
IL - Israele 3
LB - Libano 3
LV - Lettonia 3
AO - Angola 2
BO - Bolivia 2
BY - Bielorussia 2
EE - Estonia 2
ET - Etiopia 2
KG - Kirghizistan 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
GA - Gabon 1
GD - Grenada 1
HU - Ungheria 1
KZ - Kazakistan 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
Totale 9.859
Città #
Santa Clara 452
Ashburn 434
Singapore 423
Dublin 346
Fairfield 322
Southend 298
San Jose 278
Chandler 265
Hong Kong 258
Woodbridge 225
Houston 187
Jacksonville 176
Dearborn 168
Ann Arbor 162
Beijing 156
Council Bluffs 141
Chicago 139
Nyköping 131
Wilmington 120
Seattle 119
Cambridge 107
Los Angeles 107
London 88
New York 84
Hefei 82
Helsinki 79
The Dalles 69
Ho Chi Minh City 64
Modena 57
Dallas 52
Hanoi 46
Milan 46
Seoul 44
Munich 43
Rome 40
Salt Lake City 38
Moscow 37
Princeton 37
Columbus 36
Sofia 35
Buffalo 32
Eugene 32
Izmir 30
Lauterbourg 30
Shanghai 30
Jakarta 27
São Paulo 27
San Diego 26
Tampa 26
Elk Grove Village 25
Bremen 24
Bologna 22
Dong Ket 22
Orem 22
Fremont 16
Phoenix 16
Sterling 15
Lancaster 14
Naples 14
Redwood City 14
Catania 13
Boardman 12
Atlanta 11
Frankfurt am Main 11
Haiphong 11
Palermo 11
Amsterdam 10
Florence 10
Tokyo 10
Turku 10
Da Nang 9
Norwalk 9
Poplar 9
Redondo Beach 9
Toronto 9
Brasília 8
Surrey 8
Verona 8
Brooklyn 7
Chennai 7
Denver 7
Des Moines 7
Dhaka 7
Falls Church 7
Miami 7
Montreal 7
Newark 7
Rio de Janeiro 7
San Mateo 7
Tashkent 7
Warsaw 7
Baku 6
Bari 6
Belo Horizonte 6
Brescia 6
Cape Town 6
Detroit 6
Dulles 6
Ferrara 6
Johannesburg 6
Totale 6.778
Nome #
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 499
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 435
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 435
Use of Recombinant Factor IX and Thromboelastography in a Patient With Hemophilia B Undergoing Liver Transplantation: A Case Report 418
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 388
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 358
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 357
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 354
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 349
Achievements and unmet needs in the management of advanced ovarian cancer 335
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 325
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 323
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 321
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 316
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 309
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 279
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 275
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 273
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 270
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 264
Biomarkers predicting clinical benefit: fact or fiction? 259
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 250
Timing for starting second-line therapy in recurrent ovarian cancer 249
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 246
Tumori ginecologici 243
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 243
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 235
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 225
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 210
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 207
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 195
Quantitative HER2 measurement and PI3K mutation profile in matched primary and metastatic breast cancer tissues. 191
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE 184
PREDICTIVE AND PROGNOSTIC ROLE OF P53 EXPRESSION IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY: A SINGLE INSTITUTION ANALYSIS 110
Totale 9.930
Categoria #
all - tutte 36.393
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.393


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022444 0 0 57 12 11 23 27 13 64 45 121 71
2022/20231.047 97 98 58 76 71 103 13 62 403 11 29 26
2023/2024559 24 21 40 39 71 46 49 118 21 27 44 59
2024/20251.508 17 41 35 110 308 251 86 104 161 69 132 194
2025/20263.341 186 68 206 407 689 198 414 140 271 291 206 265
2026/2027370 104 193 73 0 0 0 0 0 0 0 0 0
Totale 9.930